BioNTech says Sobi's Oelkers will replace Sahin as CEO

Aug 3 (Reuters) - German biotech firm BioNTech said on Monday that Sobi's CEO Guido Oelkers will succeed Ugur Sahin as its chief executive.

Oelkers will take on the role from February 1, 2027 at latest, the company said, after serving as CEO at the Stockholm-listed biopharmaceutical company since 2017.

BioNTech announced in March its two co-founders and leading executives, Sahin and Chief Medical Officer Oezlem Tuereci, would leave the COVID-19 vaccine maker by the end of the year to start a new venture.

(Reporting by Linda Pasquini, Editing by Ludwig Burger)